Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
14 Septembre 2023 - 3:15PM
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global
clinical-stage biopharmaceutical company dedicated to discovering
and developing innovative and highly efficacious cell therapies for
the treatment of cancer, today announced that the management team
will participate in and attend one-on-one meetings at three
upcoming investor conferences.
Stifel 2023 Immunology and Inflammation Virtual
Summit Fireside Chat: Wednesday, September 20th at 10:15
am ETPresenter: Dr. Kevin Xie, Chief Financial OfficerLocation:
Virtual
Jefferies Cell & Genetic Medicine
SummitFireside Chat: Tuesday, September 26th at 9:00 am
ETOne-on-one meetings: September 26th, 2023Presenter: Dr. Kevin
Xie, Chief Financial OfficerLocation: New York
2023 Cantor Global Healthcare
ConferencePresentation: Wednesday, September 27th at 9:10
am ETOne-on-one meetings: September 27th, 2023Presenter: Dr. Kevin
Xie, Chief Financial OfficerLocation: New York
Webcast of the presentations will be available
on the News and Events section of Gracell’s investor website. A
replay of the webcast will be available for 30 days following the
event.
About Gracell Gracell
Biotechnologies Inc. (“Gracell”) is a global clinical-stage
biopharmaceutical company dedicated to discovering and developing
breakthrough cell therapies for the treatment of cancers and
autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR
technology platforms and SMART CAR™ technology module, Gracell is
developing a rich clinical-stage pipeline of multiple autologous
and allogeneic product candidates with the potential to overcome
major industry challenges that persist with conventional CAR-T
therapies, including lengthy manufacturing time, suboptimal cell
quality, high therapy cost, and lack of effective CAR-T therapies
for solid tumors and autoimmune diseases. The lead candidate
BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being
evaluated in clinical studies for the treatment of multiple
myeloma, B-cell non-Hodgkin's lymphoma and systemic lupus
erythematosus (SLE). For more information on Gracell, please visit
www.gracellbio.com. Follow @GracellBio on LinkedIn.
Media contact
Marvin Tang
marvin.tang@gracellbio.com
Investor contact
Gracie Tong
gracie.tong@gracellbio.com
Gracell Biotechnologies (NASDAQ:GRCL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Gracell Biotechnologies (NASDAQ:GRCL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024